Xylyx Bio and Cell&Soft announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.
The collaboration initially focuses on the development of products for lung adenocarcinoma. The promising early results indicated that the combination of Xylyx Bio lung-specific ECM surface coatings and Cell&Soft soft cell culture plates are compatible technologies and that lung tumor cells are highly functional in this environment. The resulting lung-specific soft cell culture products will enable scientists to develop more physiologically relevant pre-clinical tumor models to substantially improve the identification and selection of effective lung cancer therapies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
"We are excited about combining our soft cell culture plates mimicking lung rigidity with Xylyx Bio lung-specific extracellular matrix. It opens a way towards innovative and relevant products for pulmonary in vitro cell culture,” Camille Migdal, Ph.D., President and Co-Founder of Cell&Soft, said.
"Collaborative relationships with innovative companies like Cell&Soft support the creation of improved tools that enable researchers to better model disease biology and increase predictability of drug efficacy, helping shift the overall paradigm from entrenched, non-predictive in vitro models to more accurate and actionable drug discovery," Andrea Nye, President & CEO of Xylyx Bio, said.